v3.26.3
Accrued Liabilities (Tables)
9 Months Ended
Sep. 30, 2026
Accrued Liabilities, Current [Abstract]
Schedule of Accrued Liabilities
Accrued liabilities as of September 30, 2026 and December 31, 2025 consisted of the following (in thousands):
September 30,
2026
December 31,
2025
Rebates, returns and other revenue related reserves
$
180,092
$
90,504
Clinical study, manufacturing and drug supply
35,347
26,907
Compensation and benefits
62,083
69,211
Selling, general and administrative
51,895
40,026
Other
62,447
33,744
Total accrued liabilities
$
391,864
$
260,392
X
- References
No definition available.
+ Details
Name:
us-gaap_AccruedLiabilitiesCurrentAbstract
Namespace Prefix:
us-gaap_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Tabular disclosure of the components of accrued liabilities.
+ References
No definition available.
+ Details
Name:
us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock
Namespace Prefix:
us-gaap_
Data Type:
dtr-types:textBlockItemType
Balance Type:
na
Period Type:
duration